Literature DB >> 15961610

5,6-EET-induced contraction of intralobar pulmonary arteries depends on the activation of Rho-kinase.

Jennifer L Losapio1, Randy S Sprague, Andrew J Lonigro, Alan H Stephenson.   

Abstract

The mechanism mediating epoxyeicosatrienoic acid (EET)-induced contraction of intralobar pulmonary arteries (PA) is currently unknown. EET-induced contraction of PA has been reported to require intact endothelium and activation of the thromboxane/endoperoxide (TP) receptor. Because TP receptor occupation with the thromboxane mimetic U-46619 contracts pulmonary artery via Rho-kinase activation, we examined the hypothesis that 5,6-EET-induced contraction of intralobar rabbit pulmonary arteries is mediated by a Rho-kinase-dependent signaling pathway. In isolated rings of second-order intralobar PA (1-2 mm OD) at basal tension, 5,6-EET (0.3-10 microM) induced increases in active tension that were inhibited by Y-27632 (1 microM) and HA-1077 (10 microM), selective inhibitors of Rho-kinase activity. In PA in which smooth muscle intracellular Ca(2+) concentration ([Ca(2+)](i)) was increased with KCl (25 mM) to produce a submaximal contraction, 5,6-EET (1 microM) induced a contraction that was 7.0 +/- 1.6 times greater than without KCl. 5,6-EET (10 microM) also contracted beta-escin permeabilized PA in which [Ca(2+)](i) was clamped at a concentration resulting in a submaximal contraction. Y-27632 inhibited the 5,6-EET-induced contraction in permeabilized PA. 5,6-EET (10 microM) increased phosphorylation of myosin light chain (MLC), increasing the ratio of phosphorylated MLC/total MLC from 0.10 +/- 0.03 to 0.30 +/- 0.02. Y-27632 prevented this increase in MLC phosphorylation. These data suggest that 5,6-EET induces contraction in intralobar PA by increasing Rho-kinase activity, phosphorylating MLC, and increasing the Ca(2+) sensitivity of the contractile apparatus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961610     DOI: 10.1152/japplphysiol.00473.2005

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  7 in total

Review 1.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

2.  The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase.

Authors:  Hui-Hsuan Chung; Zen-Kong Dai; Bin-Nan Wu; Jwu-Lai Yeh; Chee-Yin Chai; Koung-Shing Chu; Chung-Pin Liu; Ing-Jun Chen
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  8,9-Epoxyeicosatrienoic acid analog protects pulmonary artery smooth muscle cells from apoptosis via ROCK pathway.

Authors:  Jun Ma; Lei Zhang; Shanshan Li; Shulin Liu; Cui Ma; Weiyang Li; J R Falck; Vijay L Manthati; D Sudarshan Reddy; Meetha Medhora; Elizabeth R Jacobs; Daling Zhu
Journal:  Exp Cell Res       Date:  2010-05-21       Impact factor: 3.905

4.  Simvastatin and GGTI-2133, a geranylgeranyl transferase inhibitor, increase erythrocyte deformability but reduce low O(2) tension-induced ATP release.

Authors:  K M Clapp; M L Ellsworth; R S Sprague; A H Stephenson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-01-18       Impact factor: 4.733

Review 5.  Lung Circulation.

Authors:  Karthik Suresh; Larissa A Shimoda
Journal:  Compr Physiol       Date:  2016-03-15       Impact factor: 9.090

Review 6.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

7.  Deletion of the murine cytochrome P450 Cyp2j locus by fused BAC-mediated recombination identifies a role for Cyp2j in the pulmonary vascular response to hypoxia.

Authors:  Guo Ling Zhou; Arkadi Beloiartsev; Binglan Yu; David M Baron; Weihua Zhou; Rasma Niedra; Naifang Lu; Laurel T Tainsh; Warren M Zapol; Brian Seed; Kenneth D Bloch
Journal:  PLoS Genet       Date:  2013-11-21       Impact factor: 5.917

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.